Free Trial
→ Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (From Colonial Metals) (Ad)

10 Best Penny Stocks to Buy Now - 2 of 10

Slide 2
Back to 1
Continue to 3
 
Back to 1
Continue to 3
 

CytomX Therapeutics (NASDAQ:CTMX)

Number of Upgrades from Top-Ranked Analysts
5 (in the last 90 days)
Consensus Rating
Moderate Buy
Rating Score
2.5
Ratings Breakdown
3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$5.77 (477.3% Upside)

About CytomX Therapeutics

CytomX Therapeutics logoCytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/13/2024HC WainwrightReiterated RatingNeutral
8/22/2024HC WainwrightReiterated RatingNeutral
6/27/2024HC WainwrightReiterated RatingNeutral
5/28/2024Piper SandlerUpgradeNeutral ➝ Overweight$2.25 ➝ $3.50
5/9/2024BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$3.25 ➝ $3.59
5/9/2024HC WainwrightReiterated RatingNeutral
5/9/2024WedbushUpgradeNeutral ➝ Outperform$3.00 ➝ $8.00
5/6/2024Jefferies Financial GroupUpgradeHold ➝ Buy$2.50 ➝ $8.00
5/1/2024BMO Capital MarketsReiterated RatingMarket Perform ➝ Market Perform$3.25
4/22/2024JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
Slide 2
Back to 1
Continue to 3
 

Trump Won, But Your Savings Aren’t Safe Yet (Ad)

Trump Won, But Your Savings Are Still In Danger It's the ONLY playbook that shows you how to fortify your financial future against the chaos that's coming.

Click here to get your copy now—before it's too late.

More From MarketBeat
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...
Crypto Swap Profits | Sponsored
7 Chip Stocks to Buy on the Dip
For much of the industrial era, semiconductors (i.e. chips) were a cyclical sector. For investors, that meant ...
MarketBeat
The secret supplier behind NVIDIA, Tesla and Microsoft
The Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...
Behind the Markets | Sponsored
7 High-Yield Dividend Stocks Outperforming 10-Year Treasuries
In March 2023, the yield on the 2-Year Treasury Note reached 5%. Many can remember the gut-wrenching move in m...
MarketBeat
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...
Colonial Metals | Sponsored
7 Nuclear Energy Stocks to Buy on Growing Demand
The question isn't if nuclear energy is making a comeback, but why? There are several answers, starting with t...
MarketBeat